Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Cicletanine, which has been approved and launched for hypertension in France and Germany, has
promise beyond hypertension in critically-unmet needs such as diabetes. It is evident from in
vitro, animal and human studies that cicletanine's optimal dose in diabetes and other
challenging, critically-unmet needs is likely to be higher than that for hypertension.
Cicletanine's maximum tolerated dosage is not known, but the drug's dose-limiting effects are
documented to be potassium loss and sodium loss from thiazide-type activity (one of the
therapeutic mechanisms the drug is known to have); such thiazide-type losses are known to be
reversed safely by magnesium. This trial explores the ability of magnesium to enhance
cicletanine safety at higher doses in a trial involving patients with hypertension
complicated by diabetes.